{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:56:15Z","timestamp":1794552975801,"version":"4.9.1"},"reference-count":49,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Breakthrough treatment for refractory and relapsed immune thrombocytopenia (ITP) patients is urgently needed. Autoantibody- mediated platelet clearance and megakaryocyte dysfunction are important pathogenic mediators of ITP. Glycoprotein (GP) Ib\u03b1 is a significant autoantigen found in ITP patients and is associated with poor response to standard immunosuppressive treatments. Here, we engineered human T cells to express a chimeric autoantibody receptor (CAAR) with GPIb\u03b1 constructed into the ligand-binding domain fused to the CD8 transmembrane domain and CD3\u03b6-4-1BB signaling domains. We performed cytotoxicity assays to assess GPIb\u03b1 CAAR T-cell selective cytolysis of cells expressing anti-GPIb\u03b1 B-cell receptors in vitro. Furthermore, we demonstrated the potential of GPIb\u03b1 CAAR T cells to persist and precisely eliminate GPIb\u03b1-specific B cells in vivo. In summary, we present a proof of concept for CAAR T-cell therapy to eradicate autoimmune B cells while sparing healthy B cells with GPIb\u03b1 CAAR T cells that function like a Trojan horse. GPIb\u03b1 CAAR T-cell therapy is a promising treatment for refractory and relapsed ITP patients.<\/jats:p>","DOI":"10.3324\/haematol.2023.283874","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T05:38:21Z","timestamp":1706765901000},"page":"2256-2270","source":"Crossref","is-referenced-by-count":10,"title":["GPIb\u03b1 CAAR T cells function like a Trojan horse to eliminate autoreactive B cells to treat immune thrombocytopenia"],"prefix":"10.3324","volume":"109","author":[{"given":"Jie","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"63576","doi-asserted-by":"crossref","unstructured":"Cooper N, Ghanima W. Immune thrombocytopenia. N Engl J Med. 2019; 381(10):945-955.","DOI":"10.1056\/NEJMcp1810479"},{"key":"63577","doi-asserted-by":"crossref","unstructured":"Stockelberg D, Hou M, Jacobsson S, Kutti J, Wadenvik H. Evidence for a light chain restriction of glycoprotein Ib\/IX and IIb\/ IIIa reactive antibodies in chronic idiopathic thrombocytopenic purpura (ITP). Br J Haematol. 1995; 90(1):175-179.","DOI":"10.1111\/j.1365-2141.1995.tb03397.x"},{"key":"63578","doi-asserted-by":"crossref","unstructured":"Roark JH, Bussel JB, Cines DB, Siegel DL. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood. 2002; 100(4):1388-1398.","DOI":"10.1182\/blood.V100.4.1388.h81602001388_1388_1398"},{"key":"63579","doi-asserted-by":"crossref","unstructured":"Hou M, Stockelberg D, Kutti J, Wadenvik H. Immunoglobulins targeting both GPIIb\/IIIa and GPIb\/IX in chronic idiopathic thrombocytopenic purpura (ITP): evidence for at least two different IgG antibodies. Br J Haematol. 1997; 98(1):64-67.","DOI":"10.1046\/j.1365-2141.1997.1883006.x"},{"key":"63580","doi-asserted-by":"crossref","unstructured":"McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol. 2000; 37(3):239-248.","DOI":"10.1016\/S0037-1963(00)90102-1"},{"key":"63581","doi-asserted-by":"crossref","unstructured":"Arnold DM, Dentali F, Crowther MA. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007; 146(1):25-33.","DOI":"10.7326\/0003-4819-146-1-200701020-00006"},{"key":"63582","doi-asserted-by":"crossref","unstructured":"Deshayes S, Khellaf M, Zarour A. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITP-ritux. Am J Hematol. 2019; 94(12):1314-1324.","DOI":"10.1002\/ajh.25632"},{"key":"63583","doi-asserted-by":"crossref","unstructured":"Tj\u00f8nnfjord E, Holme PA, Darne B. Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia - follow-up of the RITP study. Br J Haematol. 2020; 191(3):460-465.","DOI":"10.1111\/bjh.16672"},{"key":"63584","doi-asserted-by":"crossref","unstructured":"Canales-Herrerias P, Crickx E, Broketa M. High-affinity autoreactive plasma cells disseminate through multiple organs in patients with immune thrombocytopenic purpura. J Clin Invest. 2022; 132(12):e153580.","DOI":"10.1172\/JCI153580"},{"key":"63585","doi-asserted-by":"crossref","unstructured":"Yu TS, Wang HY, Zhao YJ. Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia. Blood Adv. 2021; 5(20):4087-4101.","DOI":"10.1182\/bloodadvances.2020003860"},{"key":"63586","doi-asserted-by":"crossref","unstructured":"Mah\u00e9vas M, Patin P, Huetz F. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest. 2013; 123(1):432-442.","DOI":"10.1172\/JCI65689"},{"key":"63587","doi-asserted-by":"crossref","unstructured":"Crickx E, Chappert P, Sokal A. Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia. Sci Transl Med. 2021; 13(589):eabc3961.","DOI":"10.1126\/scitranslmed.abc3961"},{"key":"63588","doi-asserted-by":"crossref","unstructured":"Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol. 2002; 168(7):3675-3682.","DOI":"10.4049\/jimmunol.168.7.3675"},{"key":"63589","doi-asserted-by":"crossref","unstructured":"Ellebrecht CT, Bhoj VG, Nace A. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016; 353(6295):179-184.","DOI":"10.1126\/science.aaf6756"},{"key":"63590","doi-asserted-by":"crossref","unstructured":"Oh S, Mao X, Manfredo-Vieira S. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat Biotechnol. 2023; 41(9):1229-1238.","DOI":"10.1038\/s41587-022-01637-z"},{"key":"63591","doi-asserted-by":"crossref","unstructured":"Kroll MH, Harris TS, Moake JL, Handin RI, Schafer AI. von Willebrand factor binding to platelet GpIb initiates signals for platelet activation. J Clin Invest. 1991; 88(5):1568-1573.","DOI":"10.1172\/JCI115468"},{"key":"63592","doi-asserted-by":"crossref","unstructured":"Du X. Signaling and regulation of the platelet glycoprotein Ib-IX-V complex. Curr Opin Hematol. 2007; 14(3):262-269.","DOI":"10.1097\/MOH.0b013e3280dce51a"},{"key":"63593","doi-asserted-by":"crossref","unstructured":"Nomura S, Yanabu M, Soga T. Analysis of idiopathic thrombocytopenic purpura patients with antiglycoprotein IIb\/ IIIa or Ib autoantibodies. Acta Haematol. 1991; 86(1):25-30.","DOI":"10.1159\/000204794"},{"key":"63594","doi-asserted-by":"crossref","unstructured":"Hou M, Stockelberg D, Kutti J, Wadenvik H. Antibodies against platelet GPIb\/IX, GPIIb\/IIIa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 1995; 55(5):307-314.","DOI":"10.1111\/j.1600-0609.1995.tb00702.x"},{"key":"63595","doi-asserted-by":"crossref","unstructured":"Peng J, Ma SH, Liu J. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost. 2014; 12(4):497-504.","DOI":"10.1111\/jth.12524"},{"key":"63596","doi-asserted-by":"crossref","unstructured":"Go RS, Johnston KL, Bruden KC. The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica. 2007; 92(2):283-284.","DOI":"10.3324\/haematol.10667"},{"key":"63597","doi-asserted-by":"crossref","unstructured":"Feng R, Liu X, Zhao Y. GPIIb\/IIIa autoantibody predicts better rituximab response in ITP. Br J Haematol. 2018; 182(2):305-307.","DOI":"10.1111\/bjh.14782"},{"key":"63598","doi-asserted-by":"crossref","unstructured":"Webster ML, Sayeh E, Crow M. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood. 2006; 108(3):943-946.","DOI":"10.1182\/blood-2005-06-009761"},{"key":"63599","doi-asserted-by":"crossref","unstructured":"Yu Y, Hou Y, Zhao Y. Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia. Br J Haematol. 2021; 194(1):191-194.","DOI":"10.1111\/bjh.17510"},{"key":"63600","doi-asserted-by":"crossref","unstructured":"He R, Reid DM, Jones CE, Shulman NR. Extracellular epitopes of platelet glycoprotein Ib alpha reactive with serum antibodies from patients with chronic idiopathic thrombocytopenic purpura. Blood. 1995; 86(10):3789-3796.","DOI":"10.1182\/blood.V86.10.3789.bloodjournal86103789"},{"key":"63601","doi-asserted-by":"crossref","unstructured":"Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE, Zirngibl H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood. 2000; 96(7):2520-2527.","DOI":"10.1182\/blood.V96.7.2520.h8002520_2520_2527"},{"key":"63602","doi-asserted-by":"crossref","unstructured":"Jayaraman J, Mellody MP, Hou AJ. CAR-T design: elements and their synergistic function. EBioMedicine. 2020; 58:102931.","DOI":"10.1016\/j.ebiom.2020.102931"},{"key":"63603","doi-asserted-by":"crossref","unstructured":"Zhang W, Deng W, Zhou L. Identification of a juxtamembrane mechanosensitive domain in the platelet mechanosensor glycoprotein Ib-IX complex. Blood. 2015; 125(3):562-569.","DOI":"10.1182\/blood-2014-07-589507"},{"key":"63604","doi-asserted-by":"crossref","unstructured":"Quach ME, Dragovich MA, Chen W. Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets. Blood. 131(7):787-796.","DOI":"10.1182\/blood-2017-05-784975"},{"key":"63605","doi-asserted-by":"crossref","unstructured":"Xu M, Li J, Neves MAD. GPIb\u03b1 is required for platelet-mediated hepatic thrombopoietin generation. Blood. 2018; 132(6):622-634.","DOI":"10.1182\/blood-2017-12-820779"},{"key":"63606","doi-asserted-by":"crossref","unstructured":"Huizinga EG, Tsuji S, Romijn RA. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science. 2002; 297(5584):1176-1179.","DOI":"10.1126\/science.107355"},{"key":"63607","doi-asserted-by":"crossref","unstructured":"Matsubara Y, Murata M, Sugita K, Ikeda Y. Identification of a novel point mutation in platelet glycoprotein Ibalpha, Gly to Ser at residue 233, in a Japanese family with platelet-type von Willebrand disease. J Thromb Haemost. 2003; 1(10):2198-2205.","DOI":"10.1046\/j.1538-7836.2003.00369.x"},{"key":"63608","doi-asserted-by":"crossref","unstructured":"Dong J, Schade AJ, Romo GM. Novel gain-of-function mutations of platelet glycoprotein IBalpha by valine mutagenesis in the Cys209-Cys248 disulfide loop. Functional analysis under statis and dynamic conditions. J Biol Chem. 2000; 275(36):27663-27670.","DOI":"10.1074\/jbc.M909952199"},{"key":"63609","doi-asserted-by":"crossref","unstructured":"Li J, van der Wal DE, Zhu G. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun. 2015; 6:7737.","DOI":"10.1038\/ncomms8737"},{"key":"63610","doi-asserted-by":"crossref","unstructured":"Tao L, Zeng Q, Li J. Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia. J Hematol Oncol. 2017; 10(1):46.","DOI":"10.1186\/s13045-017-0413-3"},{"key":"63611","doi-asserted-by":"crossref","unstructured":"Kosugi S, Kurata Y, Tomiyama Y. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol. 1996; 93(3):704-706.","DOI":"10.1046\/j.1365-2141.1996.d01-1702.x"},{"key":"63612","doi-asserted-by":"crossref","unstructured":"Guo L, Kapur R, Aslam R. CD20+ B-cell depletion therapy suppresses murine CD8+ T-cell-mediated immune thrombocytopenia. Blood. 2016; 127(6):735-738.","DOI":"10.1182\/blood-2015-06-655126"},{"key":"63613","doi-asserted-by":"crossref","unstructured":"Audia S, Rossato M, Trad M. B cell depleting therapy regulates splenic and circulating T follicular helper cells in immune thrombocytopenia. J Autoimmun. 2017; 77:89-95.","DOI":"10.1016\/j.jaut.2016.11.002"},{"key":"63614","doi-asserted-by":"crossref","unstructured":"Li J, Callum JL, Lin Y, Zhou Y, Zhu G, Ni H. Severe platelet desialylation in a patient with glycoprotein Ib\/IX antibody-mediated immune thrombocytopenia and fatal pulmonary hemorrhage. Haematologica. 2014; 99(4):e61-63.","DOI":"10.3324\/haematol.2013.102897"},{"key":"63615","doi-asserted-by":"crossref","unstructured":"Xiao Q, Zhang X, Tu L, Cao J, Hinrichs CS, Su X. Size-dependent activation of CAR-T cells. Sci Immunol. 2022; 7(74):eabl3995.","DOI":"10.1126\/sciimmunol.abl3995"},{"key":"63616","doi-asserted-by":"crossref","unstructured":"Leick MB, Silva H, Scarf\u00f2 I. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. 2022; 40(5):494-508.","DOI":"10.1016\/j.ccell.2022.04.001"},{"key":"63617","doi-asserted-by":"crossref","unstructured":"Lan P, Tonomura N, Shimizu A, Wang S, Yang YG. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus\/liver and CD34+ cell transplantation. Blood. 2006; 108(2):487-492.","DOI":"10.1182\/blood-2005-11-4388"},{"key":"63618","doi-asserted-by":"crossref","unstructured":"Hu Z, Yang YG. Full reconstitution of human platelets in humanized mice after macrophage depletion. Blood. 2012; 120(8):1713-1716.","DOI":"10.1182\/blood-2012-01-407890"},{"key":"63619","doi-asserted-by":"crossref","unstructured":"Othman M, Notley C, Lavender FL. Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease. Blood. 2005; 105(11):4330-4336.","DOI":"10.1182\/blood-2002-09-2942"},{"key":"63620","doi-asserted-by":"crossref","unstructured":"L\u00f3pez JA, Ludwig EH, McCarthy BJ. Polymorphism of human glycoprotein Ib alpha results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region. Structure\/function implications. J Biol Chem. 1992; 267(14):10055-10061.","DOI":"10.1016\/S0021-9258(19)50199-5"},{"key":"63621","doi-asserted-by":"crossref","unstructured":"Li CQ, Dong JF, L\u00f3pez JA. The mucin-like macroglycopeptide region of glycoprotein Ibalpha is required for cell adhesion to immobilized von Willebrand factor (VWF) under flow but not for static VWF binding. Thromb Haemost. 2002; 88(4):673-677.","DOI":"10.1055\/s-0037-1613274"},{"key":"63622","doi-asserted-by":"crossref","unstructured":"Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood. 1996; 88(1):194-201.","DOI":"10.1182\/blood.V88.1.194.194"},{"key":"63623","doi-asserted-by":"crossref","unstructured":"Fujisawa K, Tani P, McMillan R. Platelet-associated antibody to glycoprotein IIb\/IIIa from chronic immune thrombocytopenic purpura patients often binds to divalent cation-dependent antigens. Blood. 1993; 81(5):1284-1289.","DOI":"10.1182\/blood.V81.5.1284.bloodjournal8151284"},{"key":"63624","doi-asserted-by":"crossref","unstructured":"Tomiyama Y, Kosugi S. Autoantigenic epitopes on platelet glycoproteins. Int J Hematol. 2005; 81(2):100-105.","DOI":"10.1532\/IJH97.04193"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283874\/76591","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283874\/77201","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11428\/76591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:38Z","timestamp":1794045938000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283874","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}